Researchers have identified a new target for an aggressive type of blood cancer, offering a promising treatment option that could keep patients well for longer, with fewer side effects. Scientists at The Institute of Cancer Research, London, and The University of Edinburgh, discovered that blocking the TUT4/7 enzymes can significantly halt… Read More
Biotechnology company Thalia Therapeutics has acquired Sanmirna Therapeutics and its clinical-stage cancer RNA therapy. The acquisition catapults Thalia to a clinical-stage RNA therapeutics company, leveraging Sanmirna’s anti-microRNA-126 for the treatment of acute myeloid leukaemia. The deal is believed to be worth £16.675 million ($21.984 million), encompassing an initial… Read More
CERo Therapeutics has reported encouraging data from a Phase I trial evaluating a treatment for haematologic malignancies in acute myeloid leukaemia (AML). In the CERTAIN-T trial, a patient with multiple refractory AML – who had not previously achieved disease control sufficient to enable allogeneic stem cell transplantation – showed 7% bone… Read More
Biotechnology company Imviva Biotech is set to present data on its CAR-T pipeline at the American Society of Haematology (ASH) Annual Meeting. Imviva will reveal progress in allogeneic cell therapy candidates being developed for multiple haematological conditions, including T-cell acute lymphoblastic leukaemia, lymphoblastic lymphoma, acute myeloid leukaemia, B-cell… Read More
DDW Editor Reece Armstrong speaks to Michael Metzger, CEO of… Read More
Scientists have successfully used the first bioengineered bone marrow model to carry out cancer research, offering a new method which does not rely on animal models. The breakthrough, made by researchers at the University of Glasgow, represents an important step forward in being able to uncover insights into leukaemia without the… Read More
Pharmaceutical company Ipsen is set to purchase French biotechnology company ImCheck Therapeutics to develop acute myeloid leukaemia (AML) treatment ICT01. ICT01 is a first-in-class monoclonal antibody targeting BTN3A, a key immune-regulatory molecule broadly expressed across cancer, which received Orphan Drug Designations from the US Food and Drug… Read More
Biotechnology company Amphista Therapeutics has announced its nomination of AMX-883 as its first clinical development candidate for the treatment of acute myeloid leukaemia (AML). AMX-883 is a potent, selective and orally bioavailable degrader of BRD9. Leveraging Amphista’s Eclipsys platform and proprietary Targeted Glue technology, AMX-883 induces the… Read More
Pleco Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for difficult-to-treat cancers, has announced a positive outcome from its Pre-Investigational New Drug (Pre-IND) meeting with the US Food and Drug Administration (FDA). The meeting addressed the continued development of PTX-252, an intravenous (IV) formulation designed to treat… Read More
Researchers have identified a key weakness in acute myeloid leukaemia (AML), offering a promising new strategy to delay the progression of this aggressive blood cancer. The discovery focuses on disrupting the function of the nucleosome-remodelling factor (NURF) complex, which cancer cells, including leukaemia cells, rely on… Read More
The US Food and Drug Administration (FDA) has granted Fast Track designation to Sumitomo Pharma’s DSP-5336 for relapsed or refractory acute myeloid leukaemia (AML). The drug is intended for patients with a KMT2A rearrangement, also known as, mixed lineage leukaemia rearrangement (MLLr) or nucleophosmin mutation (NPM1m). Read More
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Daiichi Sankyo’s quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults with acute myeloid leukaemia (AML). Each year in the UK around 3,100 people are diagnosed with AML. Julian… Read More
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Pleco Therapeutics’s lead compound PTX-252 for the treatment of acute myeloid leukaemia (AML). PTX-252 is a novel molecular entity developed to increase the sensitivity of cancer cells to chemotherapy. The FDA’s… Read More
The University College London (UCL) has entered into a partnership with ViroCell Biologics to advance Professor Persis Amrolia’s innovative chimeric antigen receptor (CAR) T-cell therapy for relapsed paediatric acute lymphoblastic leukaemia (ALL). Dr Amrolia is Professor of Transplantation Immunology at the UCL Great Ormond Street Institute of… Read More
The US Food and Drug Administration (FDA) has approved Daiichi Sankyo’s quizartinib (Vanflyta) for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3 internal tandem duplication (ITD)-positive. It is approved with standard cytarabine and anthracycline induction and cytarabine consolidation, and… Read More
A Phase I clinical trial testing a CAR-T cell therapy treatment in children with acute myeloid leukaemia (AML) has been paused due to a patient’s death. The PLAT-08 clinical trial is a Phase I study of 2seventy bio’s cell therapy SC-DARIC33 in patients with AML. The… Read More
